Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-07-30 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Further Significant Improvement in Rett Syndrome Patients 4 pages 313.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 31 July 2024 from Neurotech International Limited reporting clinical trial results for their drug NTI164 in Rett Syndrome patients. It provides detailed clinical efficacy and safety data from a Phase I/II clinical trial extension, including statistical improvements in clinical measures and safety outcomes. The document is not a full annual or interim financial report, nor is it a regulatory filing or certification. It is a clinical update on drug development progress and trial results, which fits best under the category of a Capital/Financing Update (CAP) or Regulatory Filings (RNS). However, since it is an ASX announcement primarily focused on clinical trial progress and not fundraising or capital structure changes, and it is not a financial report, the best fit is Regulatory Filings (RNS) as a general announcement of clinical trial results and company progress. Confidence is high given the detailed clinical data and ASX announcement format.
2024-07-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 14 pages 799.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report for the period ending 30 June 2024' and contains detailed clinical trial updates, patient outcomes, and safety data for the quarter ending June 30, 2024. It includes substantive financial and operational data relevant to a quarterly period, not just a brief announcement or summary. The presence of detailed clinical results and analysis indicates this is a comprehensive interim report rather than a short announcement or press release. The document length (15,000 characters) and content depth confirm it is a full report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2024
2024-07-24 English
Phase II/III autism trial shows further benefits 3 pages 205.8KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 18 July 2024 from Neurotech International Limited reporting additional secondary endpoint data analysis from a Phase II/III clinical trial for Autism Spectrum Disorder (ASD). It details statistically significant clinical trial results, including improvements in anxiety and depression scales. The document is a detailed announcement of clinical trial results, not a full financial report or earnings release. It is not a regulatory filing or a report publication announcement since it contains substantive clinical data and analysis. The content focuses on clinical trial outcomes and their significance rather than financial performance or management commentary. Therefore, the document fits best under the category of a Capital/Financing Update (CAP) as it relates to clinical trial progress and product development updates relevant to investors and the market, which is typical for clinical-stage biopharmaceutical companies announcing trial results. Confidence is high given the detailed clinical data and the nature of the announcement.
2024-07-17 English
Significant improvement in Autism patients at 12 weeks 4 pages 370.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 July 2024 from Neurotech International Limited. It reports on clinical trial results for a Phase II/III study of NTI164 therapy in Autism Spectrum Disorder patients. The content focuses on clinical trial efficacy data, patient improvements, and safety outcomes. It is a detailed announcement of clinical trial results rather than a full financial report or regulatory filing. The document is about clinical trial progress and results, not about financial performance, management changes, or shareholder matters. It is not a full annual or interim report, nor a call transcript or investor presentation. The document is a regulatory announcement of clinical trial results, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement related to clinical trial outcomes and company progress. The document length (9374 characters) and detailed content confirm it is not a brief report publication announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-07-09 English
Investor Presentation 20 pages 1.7MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and includes detailed information about the company's business, strategy, product pipeline, market opportunity, intellectual property, and regulatory environment. It explicitly states it is a presentation prepared for investors and not an official financial report or regulatory filing. The content includes forward-looking statements, disclaimers, and detailed business strategy and market data typical of investor presentations. There is no indication of financial statements, audit information, or regulatory certifications. The length (15,000 characters) and detailed content support it being a full investor presentation rather than a brief announcement or summary. Therefore, the document fits the category of an Investor Presentation (IP).
2024-07-09 English
US FDA orphan drug designation requested for PANDAS/PANS 2 pages 113.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 9 July 2024 from Neurotech International Limited. It announces the filing for US Orphan Drug Designation with the FDA for a drug candidate NTI164. The content focuses on the regulatory filing of a request for orphan drug status, describing the drug, the condition it targets, and the expected timeline for FDA response. There are no financial statements, earnings data, or detailed management discussion. The document is a regulatory announcement about a specific regulatory filing and not a financial report, earnings release, or management report. It is not a report publication announcement since it contains substantive information about the filing itself. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-07-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.